TOKYO--(BUSINESS WIRE)--RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that the Eye has published full results from the phase 1 (SUSHI) and phase 2 (TOFU/RAMEN/TEMPURA) trials evaluating the efficacy and safety of intravitreal umedaptanib pegol in nAMD1,2. TOFU is a randomized, double-masked study assessing the efficacy of intravitreal umedaptanib pegol monotherapy or in combination with Eylea®, compared to Eylea® monotherapy in 86 subjects with anti-VEGF pretreated nAMD. RAMEN is an extension study of TOFU, in which 22 subjects who had exited the TOFU study received 4 monthly intravitreal injections of umedaptanib pegol. TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib pegol in five treatment-naïve nAMD patients.
TOKYO--(BUSINESS WIRE)--RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that it submitted an Investigational New Drug Application (IND) for an observational study to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. The purpose of the observational study is to obtain clinical basic data, including height growth, and to select subjects for the early phase II study.
TOKYO--(BUSINESS WIRE)--RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced the results from the investigator sponsored trial (IST), TEMPURA, along with updated data from its TOFU and RAMEN studies with RBM-007, an investigational anti-fibroblast growth factor-2 aptamer, in wet age-related macular degeneration (wAMD).TOKYO--(BUSINESS WIRE)--RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced the results from the investigator sponsored trial (IST), TEMPURA, along with updated data from its TOFU and RAMEN studies with RBM-007, an investigational anti-fibroblast growth factor-2 aptamer, in wet age-related macular degeneration (wAMD).
TOKYO--(BUSINESS WIRE)--RIBOMIC,nInc., a clinical stage pharmaceutical company specializing in aptamer ntherapeutics (TOKYO:4591), today announced the topline data from the nPhase 2 TOFU study of RBM-007 in patients with Wet Age-Related Macular nDegeneration (wAMD).
Ribomic announced topline data from the Phase 2 TOFU study of RBM-007 in patients with Wet Age-Related Macular Degeneration (wAMD). The double-masked, randomized, active-controlled trial enrolled 86 patients with wAMD who were previously treated with Standard of Care (antiVEGF drugs). The trial evaluated the efficacy and safety of RBM-007 monotherapy and RBM-007 in combination with Eylea compared to Eylea monotherapy. Neither RBM-007 monotherapy or RBM-007 in combination with Eylea demonstrated vision improvement over Eylea monotherapy in this patient population. Additional analyses of secondary endpoints of TOFU are ongoing.
RIBOMIC Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia
TOKYO--(BUSINESS WIRE)--RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced the presentation of preliminary interim results from the ongoing two Phase 2 studies, TOFU and the RAMEN extension study in patients with Wet Age-Related Macular Degeneration (wAMD) by Dr. Raj Maturi at the 54th Annual Scientific Meeting of the Retina Society, Chicago, USA.